Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0868 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0868 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0868 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0868 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0868 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0868 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0868 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0868 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0868 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0868 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0536 | 0.2407 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0868 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0868 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.077 | 0.7743 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0868 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0437 | 0.0151 | 0.0151 |
Brugia malayi | FAD binding domain containing protein | 0.0868 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0868 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.077 | 0.7743 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0431 | 0 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0868 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0868 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0536 | 0.2407 | 0.2407 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0868 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0868 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0868 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0431 | 0 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0868 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0868 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 6.5733 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.